Position in EXEL
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$211,382
New position
Shares Held
3,885
first reported quarter
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#579
of 751 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 47%
Shared 0%
None 53%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Baker Avenue Asset Management, LP holds $4,381,815 across 10 Biotechnology names. EXEL ranks #8 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VCEL |
Vericel Corp
|
26,219 | $1,166,483 | |
| 2 | PCVX |
Vaxcyte, Inc.
|
13,279 | $771,908 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
2,447 | $589,653 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
931 | $580,515 | |
| 5 | RPRX |
Royalty Pharma plc
|
6,991 | $391,985 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
653 | $324,364 | |
| 7 | INCY |
Incyte Corp
|
2,148 | $243,497 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
3,885 | $211,382 |
All Filings in EXEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $211,382 | 3,885 | Shares | Sole | 2026-07-28 | |
| No filing history on record for this holder in this stock. | ||||||